Skip to main content

Advertisement

SpringerLink
Log in

Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials

  • Review Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Randomized controlled trials (RCTs) showed inconsistent results regarding the efficacy of angiotensin II receptor blockers (ARBs) on portal pressure as indicated by hepatic venous pressure gradient (HVPG).

Methods

A meta-analysis of RCTs was performed to evaluate the influence of ARBs treatment on HVPG. PubMed, Embase, and Cochrane’s Library were searched for relevant RCTs. A fixed or a randomized effect model was used to pool the results according the heterogeneity. Subgroup analyses were performed to explore the source of heterogeneity.

Results

Eleven RCTs with 394 patients were included. ARBs treatment did not significantly change HVPG as compared with controls (weighted mean difference [WMD] = −0.63, 95% confidence interval [CI] −1.73 to 0.47 mmHg, p = 0.26; I2 = 60%). These results were consistent in studies comparing ARBs with propranolol (WMD = −0.40, 95% CI −2.22 to 1.41 mmHg, p = 0.67; I2 = 68%), and those comparing ARBs with non-active controls including placebo or no treatment (WMD = −1.05, 95% CI −2.33 to 0.24 mmHg, p = 0.13; I2 = 44%). These results were also not affected by the individual ARBs used. Moreover, treatment of ARBs significantly reduced mean arterial blood pressure (WMD = −6.12, 95% CI −9.69 to −2.55 mmHg, p = 0.008; I2 = 53%), and the risk of symptomatic hypotension was increased (RR = 4.13, 95% CI 0.94 to 18.18, p = 0.06; I2 = 0%).

Conclusions

ARBs did not reduce portal pressure in patients with cirrhosis; moreover, the risk of symptomatic hypotension may increase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Garcia-Tsao G, Bosch J (2010) Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 362(9):823–832. https://doi.org/10.1056/NEJMra0901512

    Article  CAS  PubMed  Google Scholar 

  2. Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383(9930):1749–1761. https://doi.org/10.1016/S0140-6736(14)60121-5

    Article  PubMed  Google Scholar 

  3. Villanueva C, Graupera I, Aracil C, Alvarado E, Minana J, Puente A, Hernandez-Gea V, Ardevol A, Pavel O, Colomo A, Concepcion M, Poca M, Torras X, Rene JM, Guarner C (2017) A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis. Hepatology 65(5):1693–1707. https://doi.org/10.1002/hep.29056

    Article  CAS  PubMed  Google Scholar 

  4. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J (2006) Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 131(5):1611–1624. https://doi.org/10.1053/j.gastro.2006.09.013

    Article  PubMed  Google Scholar 

  5. Procopet B, Berzigotti A (2017) Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf) 5(2):79–89. https://doi.org/10.1093/gastro/gox012

    Article  Google Scholar 

  6. Kim G, Kim MY, Baik SK (2017) Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis. Clin Mol Hepatol 23(1):34–41. https://doi.org/10.3350/cmh.2016.0059

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mandorfer M, Reiberger T (2017) Beta blockers and cirrhosis, 2016. Dig Liver Dis 49(1):3–10. https://doi.org/10.1016/j.dld.2016.09.013

    Article  CAS  PubMed  Google Scholar 

  8. Tripathi D, Hayes PC (2014) Beta-blockers in portal hypertension: new developments and controversies. Liver Int 34(5):655–667. https://doi.org/10.1111/liv.12360

    Article  CAS  PubMed  Google Scholar 

  9. Berzigotti A, Bosch J (2014) Pharmacologic management of portal hypertension. Clin Liver Dis 18(2):303–317. https://doi.org/10.1016/j.cld.2013.12.003

    Article  PubMed  Google Scholar 

  10. Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW (2012) Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond) 123(4):225–239. https://doi.org/10.1042/CS20120030

    Article  CAS  Google Scholar 

  11. Kim G, Kim J, Lim YL, Kim MY, Baik SK (2016) Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int 10(5):819–828. https://doi.org/10.1007/s12072-016-9705-x

    Article  CAS  PubMed  Google Scholar 

  12. Schneider AW, Kalk JF, Klein CP (1999) Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology (Baltimore, Md) 29(2):334–339. https://doi.org/10.1002/hep.510290203

    Article  CAS  Google Scholar 

  13. Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J (2010) Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol 53(2):273–282. https://doi.org/10.1016/j.jhep.2010.03.013

    Article  CAS  PubMed  Google Scholar 

  14. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S (2003) Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 98(6):1371–1376. https://doi.org/10.1111/j.1572-0241.2003.07497.x

    Article  CAS  PubMed  Google Scholar 

  15. Venon WD, Baronio M, Leone N, Rolfo E, Fadda M, Barletti C, Todros L, Saracco G, Rizzetto M (2003) Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study. J Hepatol 38(4):455–460. https://doi.org/10.1016/S0168-8278(02)00443-9

    Article  CAS  PubMed  Google Scholar 

  16. Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, Alessandria C, Bonardi R, Saracco G, Rizzetto M, Marzano A (2007) AT1 receptor antagonist candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 46(6):1026–1033. https://doi.org/10.1016/j.jhep.2007.01.017

    Article  CAS  PubMed  Google Scholar 

  17. Heim MH, Jacob L, Beglinger C (2007) The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis. Digestion 75(2–3):122–123. https://doi.org/10.1159/000104819

    Article  CAS  PubMed  Google Scholar 

  18. Schepke M, Wiest R, Flacke S, Heller J, Stoffel-Wagner B, Herold T, Ghauri M, Sauerbruch T (2008) Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. Am J Gastroenterol 103(5):1152–1158. https://doi.org/10.1111/j.1572-0241.2007.01759.x

    Article  CAS  PubMed  Google Scholar 

  19. Hidaka H, Nakazawa T, Shibuya A, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Koizumi W (2011) Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial. J Gastroenterol 46(11):1316–1323. https://doi.org/10.1007/s00535-011-0449-z

    Article  CAS  PubMed  Google Scholar 

  20. Agasti AK, Mahajan AU, Phadke AY, Nathani PJ, Sawant P (2013) Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease. J Dig Dis 14(5):266–271. https://doi.org/10.1111/1751-2980.12025

    Article  CAS  PubMed  Google Scholar 

  21. Kim JH, Kim JM, Cho YZ, Na JH, Kim HS, Kim HA, Kang HW, Baik SK, Kwon SO, Cha SH, Kim YJ, Kim MY (2014) Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Clinical and molecular hepatology 20(4):376–383. https://doi.org/10.3350/cmh.2014.20.4.376

    Article  PubMed  PubMed Central  Google Scholar 

  22. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339(jul21 1):b2535. https://doi.org/10.1136/bmj.b2535

    Article  PubMed  PubMed Central  Google Scholar 

  23. Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration www.cochranehandbook.org

  24. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327 (7414):557–560. doi:10.1136/bmj.327.7414.557, https://doi.org/10.1136/bmj.327.7414.557

    Article  PubMed  PubMed Central  Google Scholar 

  25. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186

    Article  PubMed  Google Scholar 

  26. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gonzalez-Abraldes J, Albillos A, Banares R, Del Arbol LR, Moitinho E, Rodriguez C, Gonzalez M, Escorsell A, Garcia-Pagan JC, Bosch J (2001) Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 121(2):382–388. https://doi.org/10.1053/gast.2001.26288

    Article  CAS  PubMed  Google Scholar 

  28. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, Hofer U, Caselmann WH, Sauerbruch T (2001) Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 121(2):389–395. https://doi.org/10.1053/gast.2001.26295

    Article  CAS  PubMed  Google Scholar 

  29. Castano G, Viudez P, Riccitelli M, Sookoian S (2003) A randomized study of losartan vs propranolol: effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann Hepatol 2(1):36–40

    PubMed  Google Scholar 

  30. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J (2014) Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 174(5):773–785. https://doi.org/10.1001/jamainternmed.2014.348

    Article  CAS  PubMed  Google Scholar 

  31. Wu LS, Chang SH, Chang GJ, Liu JR, Chan YH, Lee HF, Wen MS, Chen WJ, Yeh YH, Kuo CT, See LC (2016) A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan. Cardiovasc Diabetol 15:56. https://doi.org/10.1186/s12933-016-0365-x

  32. Iwakiri Y (2012) Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 32(2):199–213. https://doi.org/10.1111/j.1478-3231.2011.02579.x

    Article  CAS  PubMed  Google Scholar 

  33. Vairappan B (2015) Endothelial dysfunction in cirrhosis: role of inflammation and oxidative stress. World J Hepatol 7(3):443–459. https://doi.org/10.4254/wjh.v7.i3.443

    Article  PubMed  PubMed Central  Google Scholar 

  34. Hu ZP, Fang XL, Qian HY, Fang N, Wang BN, Wang Y (2014) Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARgamma pathway. Fundam Clin Pharmacol 28(5):501–511. https://doi.org/10.1111/fcp.12057

    Article  CAS  PubMed  Google Scholar 

  35. Kishi T, Hirooka Y, Konno S, Sunagawa K (2012) Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens 30(8):1646–1655. https://doi.org/10.1097/HJH.0b013e328355860e

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Diseases, Shandong Provincial Hospital affiliated to Shandong University, No. 9677 Jingshi Road, Lixia District, Jinan, 250014, China

    Huijing Yao & Chunqing Zhang

  2. Department of Digestive Diseases, Tai’an Central Hospital, Tai’an, 271000, China

    Huijing Yao

Authors
  1. Huijing Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunqing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chunqing Zhang.

Ethics declarations

Conflict of interest

The authors declared that they have no potential conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yao, H., Zhang, C. Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. Ir J Med Sci 187, 925–934 (2018). https://doi.org/10.1007/s11845-018-1765-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-018-1765-6

Keywords

Search

Navigation